Cambridge Epigenetix
Business Services · United Kingdom · 11-50 Employees
View Company Info for Free
Overview
Headquarters
The Trinity Building Chesterford Researc...Phone Number
+44 1223804260Website
www.cambridge-epigenetix.comRevenue
$8.9 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Cambridge Epigenetix
biomodal specializes in advanced multiomics technologies that enable the simultaneous capture of genetic and epigenetic information from a single biological sample. Their innovative duet multiomics solutions, evoC and +modC, facilitate in-depth analysis essential for research in cancer, neurodegenerative diseases, and precision medicine. By providing insights into the 6-base genome, the company empowers researchers to better understand normal and disease biology. Their products are designed for scientists and researchers in the fields of genomics and biotechnology.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cambridge Epigenetix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Cambridge Epigenetix recently announced quarterly report
Check out if Cambridge Epigenetix is spiking on competitors!
Check if Cambridge Epigenetix has recently received funding, and reach out quickly before it becomes old news!
Cambridge Epigenetix, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Cambridge Epigenetix launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Cambridge Epigenetix has new funding data
Click to see if Cambridge Epigenetix had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Cambridge Epigenetix
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Cambridge Epigenetix
Compare insights from companies similar to Cambridge Epigenetix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Cambridge Epigenetix
$8.9M
11-50
Private
$144.5M
2012
N/A
Company Profile Activity
Activity Insights
Cambridge Epigenetix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Cambridge Epigenetix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Cambridge Epigenetix.
Cambridge Epigenetix financials insights
Gather financial insights about Cambridge Epigenetix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$5.5M
2016
Series B
$21M
2018
Series C
$30M
2021
Series D
$88M
Cambridge Epigenetix Tech Stack
A closer look at the technologies used by Cambridge Epigenetix
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
Open Position
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cambridge Epigenetix
Sign Up For FreeTo access detailed company insights
biomodal specializes in advanced multiomics technologies that enable the simultaneous capture of genetic and epigenetic information from a single biological sample. Their innovative duet multiomics solutions, evoC and +modC, facilitate in-depth analysis essential for research in cancer, neurodegenerative diseases, and precision medicine. By providi... Read More
